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A B S T R A C T
Platinum-based drugs such as cisplatin are very potent chemotherapeutics, whereas radioactive platinum (195mPt)
is a rich source of low-energy Auger electrons, which kills tumor cells by damaging DNA. Auger electrons damage
cells over a very short range. Consequently, 195mPt-based radiopharmaceuticals should be targeted toward tumors
to maximize radiotherapeutic efficacy and minimize Pt-based systemic toxicity. Herein, we show that systemically
administered radioactive bisphosphonate-functionalized platinum (195mPt-BP) complexes specifically accumulate
in intratibial bone metastatic lesions in mice. The 195mPt-BP complexes accumulate 7.3-fold more effectively in
bone 7 days after systemic delivery compared to 195mPt-cisplatin lacking bone-targeting bisphosphonate ligands.
Therapeutically, 195mPt-BP treatment causes 4.5-fold more γ-H2AX formation, a biomarker for DNA damage in
metastatic tumor cells compared to 195mPt-cisplatin. We show that systemically administered 195mPt-BP is radi-
otherapeutically active, as evidenced by an 11-fold increased DNA damage in metastatic tumor cells compared to
non-radioactive Pt-BP controls. Moreover, apoptosis in metastatic tumor cells is enhanced more than 3.4-fold
upon systemic administration of 195mPt-BP vs. radioactive 195mPt-cisplatin or non-radioactive Pt-BP controls.
These results provide the first preclinical evidence for specific accumulation and strong radiotherapeutic activity
of 195mPt-BP in bone metastatic lesions, which offers new avenues of research on radiotherapeutic killing of tumor
cells in bone metastases by Auger electrons.
1. Introduction
Auger electrons are low-energy electrons emitted by specific radio-
nuclides, which decay by electron capture. Auger-emitting radiopharma-
ceuticals are promising candidates for cancer treatment because the
energy is deposited over a very short range in the order of nanometers [1].
195mPt is known for its high Auger emission intensity since this radionu-
clide emits 36 Auger electrons per decay, which exceeds the number of
Auger electrons emitted by 111In (7), 123I (14), and 125I (23) by
far. Consequently, 195mPt-based Auger therapy would enable potent
effective killing of tumor cells if delivered within the vicinity of a tumor
cell, as the energy deposited per decay ismuch higher for 195mPt (2000 eV)
as compared with 111In (450 eV), 123I (550 eV), or 125I (1000 eV) [2].
Platinum (Pt)-based drugs are widely used for the treatment of 24
specific types of cancer [3]. Traditional Pt drugs such as cisplatin consist
of two non-leaving amine groups and two additional leaving ligands that
can bind DNA to induce DNA damage [4]. Cisplatin comprising radio-
active Pt core (191Pt, 193mPt, and 195mPt) has been explored between
1990 and 2000 as an alternative to cisplatin for both tumor imaging and
therapy [5,6], since cisplatin also acts as a radiosensitizer by enhancing
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the efficacy of radiation therapy [7]. However, clinical translation of
radioactive Pt was hampered by its non-targeted tissue uptake leading to
severe side-effects such as nephrotoxicity.
Fortunately, a novel generation of bone tumor–targeting Pt-based
drugs has been developed recently to minimize toxicity (e.g. nephro-
toxicity) and maximize therapeutic antitumor efficacy [8–10]. Margiotta
et al. functionalized Pt with bisphosphonate ligands (Pt-BP) to facilitate
the design of Pt-based chemotherapeutics targeting bone of high meta-
bolic activity such as bone metastases [11–14]. These Pt-BP complexes
were shown to act as prodrugs by dissociating into free bisphosphonate
ligands and chemotherapeutically active Pt-species able to kill cancer
cells in a manner similar to BP-free Pt drugs following their dissociation
(Fig. 1A) [14].
Previously, we successfully synthesized radioactive 195mPt-BP com-
plex to facilitate targeting of Auger-emitting 195mPt to bone metastases
[15]. This novel radioactive complex accumulated specifically in bone of
high metabolic activity. For optimal treatment of bone tumors, these
195mPt-BP complexes should release 195mPt species specifically at the
tumor site to enable uptake by tumor cells, reaction with DNA, and for-
mation of 195mPt-DNA adducts to trigger tumor cell killing. Release ki-
netics of Pt species from Pt-BP complexes attached to hydroxyapatite
mineral are typically slow, but are accelerated at reduced pH [12,14,15].
Therefore, we hypothesize that targeting 195mPt-BP to metastatic bone
lesions will trigger local release of 195mPt near cancer cells upon vigorous
bone remodeling and osteolytic resorption at reduced pH.
Herein, we provide solid evidence to prove our previously made claim
on bone tumor-targeting of 195mPt-BP complexes [15]. In more detail, we
confirm for the first time that 195mPt-BP complexes are indeed specif-
ically targeted to bone metastases because of their high metabolic ac-
tivity. First, we establish a bone metastasis model by intratibial injection
of human prostate cancer cells and validate this model by monitoring
bone metabolic activity (using 99mTc-methylenediphosphonate
[99mTc-MDP], micro–single-photon emission computed tomography/-
computed tomography [micro-SPECT/CT] imaging) and lesion forma-
tion (using ex-vivo high-resolution micro-CT imaging) (Fig. 1B). Second,
we confirm specific accumulation of 195mPt-BP (but not of 195mPt-cis-
platin) in these tibial metastatic lesions using micro-SPECT/CT imaging
(Fig. 1C). To compare the therapeutic efficacy of radioactive 195mPt-BP
vs. 195mPt-cisplatin vs. non-radioactive Pt-BP species, we perform
immunostainings to detect DNA damage and apoptosis in tibial meta-
static lesions [16]. Overall, we provide the first preclinical evidence for
the radiotherapeutic efficacy of Auger therapy for the treatment of bone
metastases using 195mPt-BP complexes, which stresses the novelty and
potential impact of our approach.
2. Methods
2.1. Study design
The objective of the study was to confirm the bone tumor–targeting
potential of 195mPt-BP complexes and localize Auger electron-emitting
195mPt radionuclides specifically within intratibial bone metastases. To
this end, we first validated our intratibial bone metastasis model using
99mTc-MDPmicro-SPECT/CT imaging and ex vivo high-resolution micro-
CT imaging. Blinding was applied in housing. In addition, biotechnicians
were also blinded upon administration of different treatments. The mice
were monitored for behavioral and bodily changes daily, starting at day
0 to prevent excessive discomfort due to excessive tumor growth,
swelling, loss of body weight, and/or abdominal circumference. The
following humane endpoints were considered as indications for the need
of euthanasia: a) body weight gain of >20% within 10 days caused by
tumor growth; b) no water or food intake; c) weight loss of>15% per 1–2
days or>20% of initial body weight; d) serious circulatory or respiratory
problems; e) behavioral changes (hyperactivity, passive, automutilation)
and locomotion problems; f) morbidities such as impaired mobility, ne-
crosis, or lethargy; and g) excessive tumor growth leading to bone
fractures. Image acquisition and data analysis of the in vivo and ex vivo
data were performed in a non-blinded manner.
2.2. Materials
Na2SO4 and Ba(OH)2 were purchased from Sigma-Aldrich. 2-Amino-
1-hydroxyethane-1,1-diyl-bisphosphonic acid (AHBP-H4) was prepared
following procedures reported previously [12]. XenoLight D-Luciferin
was purchased from PerkinElmer (The Netherlands). Milli-Q water was
used to dissolve the compounds. All other reagents were purchased from
Sigma-Aldrich and used without further purification.
2.3. Cell culture
The breast cancer cell line (MDA-MB-231-eGFP) was provided by Dr.
ManjaWobus (Department of Medicine I, University Hospital Carl Gustav
Carus, Technische Universit€at Dresden, Germany). The prostate cancer
cell line (PC3-eGFP and PC3-luc) was provided by Dr. Egbert Oosterwijk
(Department of Urology, Radboud University Medical Center, Radboud
Institute for Molecular Life Sciences, 6500 HB, Nijmegen). Cancer cell
lines were maintained at 37 C with 5% CO2 in log phase. Breast cancer
cells were cultured using DMEM (Dulbecco's Modified Eagle Medium,
Gibco) supplemented with 10 vol.% fetal bovine serum (FBS, Lonza) and
1% geneticin (G418). Prostate cancer cells were cultured using RPMI
(Roswell Park Memorial Institute) 1640 medium (Gibco) supplemented
with 10 vol.% FBS (Lonza) and 5 μg/ml puromycin.
2.4. In vivo models
All in vivo studies were conducted in accordance with ISO standards
and the principles set forth by the Revised Dutch Act on Animal Exper-
imentation. The in vivo experiments were approved by the institutional
Animal Welfare Committee of the Radboud University Medical Center
(Radboudumc), Nijmegen, the Netherlands. For the in vivo experiment,
male BALB/cAnNRj-Foxn1nu/Foxn1nu (athymic nude) mice (Charles
River), with an average weight of ~25 g and an age of approximately 6–8
weeks, were housed in filter-topped cages (5 mice per cage) under non-
sterile standard conditions provided with standard animal food and
water ad libitum. The mice were allowed to adapt to laboratory condi-
tions for 1 week before experimental use.
For intratibial injection, the mice were anesthetized via isoflurane
inhalation. PC3-eGFP or MDA-MB-231-eGFP or PC3-luc (2  105) cells
suspended in 20 μl cold PBS (phosphate-buffered saline) was injected into
the right tibia, whereas only cold PBS was injected into the contralateral
left tibia of BALB/cAnNRj-Foxn1nu/Foxn1nu mice using 30G needles (BD
Micro-Fine). Analgesia was provided with buprenorphine (0.5 mg/ml)
once before the intratibial injection. For validation of the bone metastasis
model, PC3-eGFP and MDA-MB-231-eGFP cell lines were used. After
intratibial injection of PC3-eGFP or MDA-MB-231-eGFP, mice were ran-
domized into three groups, corresponding to weeks 1, 3, and 5 (6–8 mice
per group). For the biodistribution study, PC3-luc cell lines were used.
After intratibial injection of PC3-luc, mice were followed biweekly using
bioluminescence imaging to confirm tumor growth and 18F-NaF PET
(positron emission tomography) imaging to confirm tumor-induced for-
mation of lesions. Mice bearing tibial lesions were equally and randomly
distributed by a biotechnician into four groups (n ¼ 4) to be treated with
195mPt-BP, 195mPt-cisplatin, Pt-BP, or saline control. 195mPt/Pt complexes
were administered intravenously (single dose) 1 day after randomization,
followed by euthanasia after 2 weeks or at a humane endpoint.
2.5. Validation of bone metastasis mice model using 99mTc-Medronate
99mTc-medronate was prepared as per the protocol provided by MDP
multidose kit (GE Healthcare, The Netherlands). All mice received an
intravenous injection with a dose of approximately 37 MBq 99mTc
through the tail vein. Immediately after 1 hpostinjection, images were
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acquired using a U-SPECT-II/CT (MILabs), as reported previously [15,17,
18]. The following criteria were used to confirm the tibial lesion for-
mation: a) visual confirmation of 99mTc-uptake below the growth plate in
right tibia compared to contralateral control tibia; b) at least 10%
99mTc-uptake increase in tibial lesion region of interest (ROI) below
growth plate compared to contralateral control tibia.
2.6. SPECT imaging
Mice were scanned using a U-SPECT-II/CT (MILabs) under general
anesthesia (isoflurane/O2) for 15 min using the 1.0-mm diameter pinhole
mouse high sensitivity collimator tube, followed by a CT scan (spatial
resolution 160 mm, 65 kV, 615 mA) for anatomical reference. Scans were
reconstructed with MILabs reconstruction software using an ordered-
subset expectation-maximization algorithm, with a voxel size of 0.4
mm. SPECT/CT scans were analyzed and maximum intensity projections
were created using the Inveon Research Workplace software (IRW,
version 4.1). A three-dimensional (3D) volume of interest (VOI) was
drawn using CT threshold (CT value: soft tissue is 11–39% and skeletal
tissue is 41–100%) to differentiate soft tissue from skeletal tissue, and
uptake was quantified as the percentage injected dose per gram (%ID/g)
using standard curve, assuming a tissue density of 1 g/cm3. The hot spot
Fig. 1. Schematic representation of study design. (A) Chemical structure of Pt-BP and activation to pharmacologically active Pt-species. (B) Validation of an intratibial
bone metastasis model using micro-SPECT/CT imaging and ex-vivo high-resolution micro-CT imaging at weeks 1 (W1), 3 (W3), and 5 (W5). (C) Establishment of an
intratibial bone metastasis model monitored biweekly using 18F-NaF PET imaging and bioluminescence imaging. Mice bearing tibial lesions were randomized into four
treatment groups: 195mPt-BP, 195mPt-cisplatin, Pt-BP, and saline control. 195mPt biodistribution was followed by micro-SPECT/CT imaging in mice bearing tibial lesions
at 1 h, 24 h, and 7 days after administration. Tibial lesion and contralateral control tibia were analyzed using ex-vivo high-resolution micro-CT and histological
methods. (Images were created using Biorender.)
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in the skeletal tissue ROI was chosen with the location of the edge of the
ROI contour representing 75% of maximum intensity. All mice were
euthanized with CO2 after micro-SPECT/CT imaging.
2.7. Validation of bone metastases using high-resolution X-ray CT (HR-
microCT)
After harvesting, the tibias were fixed in a freshly prepared 4% para-
formaldehyde solution for 1 day and transferred to 70% ethanol for
storage. Subsequently, they were scanned at 5 μm resolutions using HR-
microCT (Phoenix NanoTom S, GE Measurement and Control Solutions),
as reported [19]. HR-microCT images were generated on the X-ray CT
facility of the Department of Development and Regeneration of the KU
Leuven, financed by the Hercules foundation. The source was equipped
with a tungsten target and operated at 70 kV and 120 μA. An aluminum
filter of 0.5 mm was applied to reduce beam hardening. A fast mode
setting (i.e. exposure time 500 ms, frame averaging 1 and skip 0) was used
and the scanning time was 8 min per sample. Images were analyzed using
CTAn (Bruker MicroCT, Kontich, Belgium), as reported [19]. The recon-
structed images were rotated in 3D and saved with the tibia growth plate
aligned at 90 with the z-axis of the image stack (DataViewer software,
v1.5.6.2, SkyScan-Bruker). Trabecular and cortical bone parameters were
not analyzed separately because of the massive destruction of the bone
architecture. To determine bone loss, we selected 1,400 images (7 mm
height) starting at 500 μm below the growth plate level. On this data set, a
ROI was drawn manually, incorporating both the trabecular structure and
the cortical bone. Using 3D analysis, bone volume fraction (BV/TV) and
bone volume (BV) were calculated. Tibial lesion was considered to be
established only if at least 5% change in total bone volume within ROI
compared to contralateral tibia was observed. The selected ROI was
visualized in 3D using CTVox (Bruker MicroCT, Kontich, Belgium).
2.8. Bioluminescence imaging
After intratibial injection of PC3-luc cells in mice right tibia, tumor
growth in tibias was monitored by measuring luciferase activity using
real-time in vivo imaging by means of an IVIS Lumina II system (Caliper
Life Sciences, Hopkinton, MA), as described previously [20]. In brief,
200 μl D-luciferin (150 mg/kg of mice body weight; PerkinElmer, The
Netherlands) dissolved in PBS were injected subcutaneously 5 min before
imaging the mice. After anesthetization by isoflurane, mice were imaged
using a field of view of 12.5 cm, medium binning factor and an exposure
time of 60 s. Luminescence intensity was visualized using the Living
Image 4.5 software (Caliper Life Sciences), shown as rainbow plots with
automatic scale bars per measurement and represented as radiance units
(photons/second/cm2/steradian).
2.9. PET imaging
All mice injected with PC3-luc cells in the tibia (right leg) received an
intravenous injection biweekly (W2 and W4) with a dose of approxi-
mately 9 MBq 18F-NaF. PET imaging was performed by scanning four
mice simultaneously per acquisition. Mice were imaged under general
anesthesia (2–3% isoflurane/O2) for 15 min at 1 hafter administration.
Scans were reconstructed using Inveon Acquisition Workplace software
with iterative 3D ordered-subsets expectation maximization using a
maximum a priori algorithm with shifted Poisson distribution, with the
following parameters: matrix 256 256 161, pixel size 0.4 0.4 0.8
mm, with a corresponding beta of 0.05 mm, as reported previously [21].
2.10. In vivo biodistribution of 195mPt-agents in the prostate cancer
cell–induced bone metastasis mouse model
195mPt-cisplatin (radioactive cisplatin; radionuclide purity > 98%)
and [195mPt(NO3)2(en)] (en ¼ ethylenediamine; radionuclide purity >
95%) were kindly provided by NRG (Petten, the Netherlands). 195mPt-BP
was synthesized using [195mPt(NO3)2(en)] as precursor in a similar
manner as described for non-radioactive Pt-BP (see Supplementary Ma-
terials). The pH of 195mPt-cisplatin was neutralized to pH 7 using 1 M
NaOH and reconstituted in a sterile saline solution. Characterization of
195mPt-BP or 195mPt-cisplatin via elemental analysis and Electrospray
Ionization–Mass Spectrometry was not possible because of an insufficient
amount of residual radioactive platinum compounds. Radionuclide pu-
rity was approximately similar, as previously reported [15,22].
195mPt-BP, 195mPt-cisplatin, and Pt-BP were reconstituted in 200 μl
sterile saline solution (0.9% NaCl) and administered intravenously in the
tail vein of BALB/cAnNRj-Foxn1nu/Foxn1nu mice (n ¼ 4 per each plat-
inum complex). Mice treated with 195mPt-BP received an intravenous
injection with a dose of 9.0  0.1 MBq (3.4 mM). Mice treated with
195mPt-cisplatin group received an intravenous injection with a dose of
5.2  0.2 MBq (2.5 mM), ensuring Pt dose was below the Pt toxicity dose
of 6 mg/kg for mice [23]. Based on previous results showing toxicity for
radioactive cisplatin (but not for 195mPt-BP) at doses >6 mg/kg, we used
a 195mPt-cisplatin dose below that threshold [15,22]. Inherently, the
radioactive dose of 195mPt-cisplatin (5.2  0.2 MBq) was relatively half
compared to that of 195mPt-BP (9.0  0.1 MBq). The mice treated with
Pt-BP received an intravenous injection of Pt-BP (0.6 mg per mice) cor-
responding to the platinum concentration in the 195mPt-BP group.
Immediately after injection of 195mPt-BP or 195mPt-cisplatin, images were
acquired using a U-SPECT-II/CT system (MILabs) at 1 h, 24 h, and 7 days
as reported previously for 99mTc-medronate [15]. Whole-body SPECT/CT
imaging was performed at 1 h and 24 h, whereas only the lower part of
mice including the tibias was scanned at day 7 because of reduced
radioactivity in the ROI at this time point (<1%ID). SPECT/CT scans
were analyzed as reported earlier for 99mTc-medronate [15]. At the end
of the experiment, mice were euthanized, tibias were harvested, and
fixed in a 4% formalin buffer for 48 h.
2.11. Immunohistochemical and histochemical staining
After fixation, tibia samples from each group were decalcified in an
EDTA (ethylenediaminetetraacetic acid) solution, dehydrated in a series
of alcohol, and embedded in paraffin, as reported previously [24]. The
specimens were sectioned at a thickness of 5 μm using a standard
microtome (RM 2165; Leica). All sections were cut parallel to the long
axis of the tibia. Sections were mounted in triplicate on a glass slide. For
each tumor tibia, different stainings were performed on adjacent sections
for better correlation. Hematoxylin and eosin (H&E) staining was per-
formed as reported previously [25].
Immunostaining of γ-H2AX using rabbit anti-human γ-H2AX antibody
(2577s, Cell Signaling Technology; diluted 1:400) was performed as
previously described [26]. Paraffin sections were rehydrated in a series of
decreasing concentrations of ethanol, and antigen was retrieved in so-
dium citrate buffer (pH 6.0) at 70 C for 10 min. Subsequently, slides
were blocked with 10% normal donkey serum (NDS), and then incubated
with the primary antibody overnight at 4 C. Slides were then treated
with a biotin-conjugated secondary antibody (Chemicon, Temecula,
USA) for 1 hat room temperature, followed by counterstaining with
methyl green. Negative controls using 2% NDS instead of the primary
antibody were generated in parallel to ensure that the staining was
specific. In addition, PC3-luc cells cultured in vitro were used as negative
controls, whereas X-ray (2 Gy dose; XRAD 320 ix; Precision XRT; N.
Brandford, CT, USA) irradiated PC3-luc cells cultured in vitro were used
as positive controls. Finally, the sections were dehydrated and mounted.
Apoptotic tumor cells were evaluated by FragEL DNA fragmentation
detection kit (QIA33-1EA, EMD Millipore) with the colorimetric TdT
enzyme (Calbiochem), following the manufacturer's protocol. Counter-
staining with methyl green was performed for immunohistochemical
staining of γ-H2AX and FragEL DNA fragmentation detection to aid in the
morphological evaluation.
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2.12. Histological image analysis
All stained sections were scanned using an Olympus slide scanner
(Olympus Nederland B.V.). Images were digitally viewed and cropped at
a 10 zoom level using Olympus OlyVIA software (v2.9). The effect of
195mPt on the induction of DNA double-strand breaks was evaluated by
immunohistochemical staining of γ-H2AX within the tumor ROI. At 10
objective magnification, three different sections (n ¼ 3 per section) per
tumor tibia at a distance of 100 μm from each other were prepared from
the tumor-bearing tibias. Four random microscopic images at 10 were
obtained in the ROI within each section. To quantify colorimetric DAB
(3,30-diaminobenzidine) signal area of γ-H2AX-immunostaining, images
were analyzed using ImageJ (version 1.52p) as reported earlier [27–29].
The images were selected in ImageJ, and the ROI was drawn within the
selected images to determine the total tumor area. This procedure was
followed by color thresholding to manually filter the DAB-stained area
(dark brown) within the tumor ROI. The area corresponding to
DAB-stained regions was measured. In addition, negative controls in the
same slide were also analyzed as described earlier for each sample image
to detect and eliminate false-positive values. Finally, an area-based
analysis was used to extract a percentage of γ-H2AX positive tumor cell
areas within the tumor ROI from each image. Similarly, the apoptotic
tumor cell area was determined by FragEL DNA fragmentation detection
to extract a percentage of apoptosis-positive tumor cell areas within the
tumor ROI from each image.
2.13. Statistical analysis
Data for all parameters are expressed as means  standard deviation.
The statistical analyses were performed using GraphPad Prism (version
6.0) software. Two-way analysis of variance (ANOVA) with a Bonferroni
(multiple comparisons) posthoc test was used to determine the differ-
ences among the two groups at different time points. For histology data,
one-way ANOVA with a Turkey (multiple comparisons) posthoc test was
used. For all statistical analysis, a value of p was considered as signifi-
cantly different if *p  0.05; **p  0.01; ***p  0.001; ****p  0.0001.
3. Results
3.1. Establishment and validation of metastatic lesions in mouse tibia
Bone metastases were established in the tibia of male athymic nude
mice by intratibial injection of breast cancer cells (MDA-MB-231) or
prostate cancer cells (PC3). Breast cancer is known to induce osteolytic
lesions, whereas prostate cancer induces mixed lesions for these specific
cell lines [30,31]. Hence, the induction of osteolytic or mixed lesions was
validated at weeks 1 (W1), 3 (W3), and 5 (W5) after intratibial injection.
We quantitatively assessed bone metabolism by 99mTc-MDP uptake in the
cancer cell–injected tibia (tibial lesion; right leg) and the PBS-injected
tibia (control tibia; left leg) using micro-SPECT/CT imaging at 1 hafter
administration. Furthermore, ex-vivo high-resolution micro-CT imaging
of the tibial lesion and control tibia was performed to quantify the change
in BV and BV/TV (BV in the total VOI). The corresponding quantification
of the establishment of tibial lesions is summarized in Table S1.
Micro-SPECT/CT imaging of 99mTc-MDP confirmed that tibial lesions
were successfully established, as evidenced by increased bone meta-
bolism at W5 for both prostate and breast cancer cell–induced lesions.
Breast cancer cells often induced additional distant metastases, especially
in the spine at W1 and W3 (Fig. S1A). However, injected prostate cancer
cells induced localized tibial lesions of high metabolic activity (Fig. S1B).
At W5, 99mTc-MDP uptake in both types of tibial lesions was significantly
higher (breast cancer: p< 0.0042, prostate cancer: p< 0.0001) compared
with the contralateral control tibia (Fig. 2A). However, bone metabolic
activity was higher in lesions induced by prostate cancer cells (10.1 
1.8% ID/g) vs. breast cancer cells (3.8 0.7% ID/g). The selective uptake
of 99mTc-MDP in tibial lesions at W5 (relative to lesion-free control tibias)
was also higher in lesions induced by prostate vs. breast cancer cells
(Fig. 2B). Bone volume fraction and total bone volume of breast cancer
cell–induced tibial lesions decreased from W1 to W5 because of osteo-
lytic destruction of cortical bone (Fig. 2C and D), whereas prostate cancer
cell–induced lesions showed a constant bone volume fraction. Further-
more, both bone volume fraction (Fig. 2C, at W3 and W5) and total bone
volume (Fig. 2D, at W5) were higher for lesions induced by prostate vs.
breast cancer cells. Ex-vivo high-resolution micro-CT imaging confirmed
that breast cancer cells predominantly induced osteolytic lesions,
whereas prostate cancer cells induced osteosclerotic lesions at W3 and
mixed osteosclerotic/osteolytic lesions at W5 (Fig. 2E and F).
In brief, we conclude that intratibial injection of breast cancer cells
result in tibial lesions with osteolytic activity as well as additional distant
metastases in other parts of the skeleton. In contrast, intratibial injection
of prostate cancer cells induce localized and mixed osteosclerotic/
osteolytic tibial lesions of increased metabolic activity. Consequently, we
selected the prostate cancer cell–induced intratibial bone metastasis
model to evaluate the targeting and therapeutic potential of 195mPt-BP
complexes.
3.2. 195mPt-BP specifically accumulates within tibial bone metastatic
lesions
Using the intratibial prostate cancer cell–induced bone metastasis
model, lesion formation and tumor growth in tibial lesions were
measured biweekly using 18F-NaF PET imaging (Fig. S2) and biolumi-
nescence imaging (Fig. S3), respectively. The uptake of 18F-NaF corre-
sponds to changes in bone remodeling, whereas prostate cancer cells
expressing luciferase facilitate longitudinal monitoring of tumor
confinement [32,33]. Mice bearing tibial lesions received one of four
different treatments in a randomized manner (4 weeks after intratibial
injection, n ¼ 4): 195mPt-BP, 195mPt-cisplatin, Pt-BP, and saline control.
As previous results showed toxicity for radioactive cisplatin at doses >6
mg/kg (but not for 195mPt-BP), we used a 195mPt-cisplatin dose below this
threshold [15,22]. Inherently, the radioactive dose of 195mPt-cisplatin
(5.2  0.2 MBq) was lower compared with 195mPt-BP (9.0  0.1 MBq).
Ex-vivo high-resolution micro-CT imaging confirmed the formation of
mixed osteosclerotic/osteolytic lesions in all mice except for three mice
(1 195mPt-BP, 1 Pt-BP, and 1 saline control) (Fig. S4). The bone
volume within the metastatic lesion area increased with>15% compared
with the contralateral control tibia for all treatment groups (Table S2).
Nevertheless, the bone volume fraction after W6 varied considerably
between mice because of the massive destruction of normal bone archi-
tecture (Table S2).
195mPt-BP showed rapid bone tumor–targeted accumulation of
195mPt in tibial lesions already 1 hafter systemic administration,
whereas skeletal uptake of 195mPt-cisplatin was not observed for the
entire study period (Fig. 3A and B). The uptake of 195mPt-BP in meta-
static lesions was pronounced after 1 h (7.9  0.3%ID/g, 22 μg of Pt/g),
slightly decreased to 6.1  0.5%ID/g (17 μg of Pt/g) at 24 h, and
remained almost constant until day 7 (5.9  1.1%ID/g, 16.4 μg of Pt/g).
On the other hand, 195mPt-cisplatin exhibited significantly lower (p <
0.0001) uptake in the lesions at all time points, as reflected by uptake
values of 3.7  0.8%ID/g (4.1 μg of Pt/g) at 1 h, 2.4  0.3%ID/g (2.7 μg
of Pt/g) at 24 h, and 1.6  0.6%ID/g (1.8 μg of Pt/g) at day 7 (Fig. 4A).
To determine selective uptake of 195mPt in the metastatic tibia, 195mPt
uptake was normalized to uptake in the contralateral lesion-free control
tibia. 195mPt-BP uptake was selective considering the 2.8 (0.6)-fold (at
1 h and 24 h) to 3.3 (2.2)-fold (at day 7) increased uptake in tibial
lesions (Fig. 4B). In contrast, 195mPt-cisplatin showed similar 195mPt
uptake in both metastatic and lesion-free control tibias at 1 h and 24 h.
Targeting of 195mPt-BP for metastatic lesions was further confirmed by
its higher uptake compared to 195mPt-cisplatin at 1 h, 24 h(2.7-fold),
and 7 days (7.3-fold). Summarizing, these results clearly confirm that
the BP ligand of 195mPt-BP facilitates targeted accumulation of 195mPt in
prostate cancer cell–induced tibial lesions.
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By applying CT thresholding, we were able to discriminate between
accumulation of 195mPt in soft tissue surrounding the lesion vs. skeletal
tissue of the lesion (Fig. 4C). 195mPt-BP showed almost similar accumu-
lation (range: 1.8–2.1 %ID/g; 5.0–5.8 μg Pt/g) in soft tissue surrounding
the tibial lesion at all time points. Similarly, 195mPt-cisplatin also showed
constant accumulation levels in soft tissue surrounding the tibial lesion at
all time points, albeit at significantly lower (p < 0.001) values (0.3 
0.3%ID/g, 0.3 μg of Pt/g). Generally, accumulation of 195mPt-BP in soft
tissue surrounding the tibial lesion was three-fold lower than uptake in
the entire tibial lesion after 24 hand remained constant until day 7.
Similar to 195mPt accumulation in the tibial lesion, accumulation of
195mPt-BP in soft tissue surrounding the tibial lesions was also selective
(Fig. 4D). These results demonstrate that targeted accumulation of
195mPt-BP in tibial lesions also increases the 195mPt level in soft tissue
surrounding these lesions by a factor 5.5 (at 1 h) and 6.2 (at 24 hand 7
days) compared to 195mPt-cisplatin.
Furthermore, we analyzed the total uptake of 195mPt uptake in the soft
vs. skeletal tissues of the entire mouse to differentiate the 195mPt uptake
in non-targeted tissue compared to targeted tissue (Fig. 4E). 195mPt-BP
mainly accumulated in skeletal tissue (3.2 0.7%ID/g, 8.9 μg of Pt/g) at
1 hafter injection, which reduced to 2.6  0.5%ID/g (7.2 μg of Pt/g) at
24 h. 195mPt-BP uptake was significantly lower (p < 0.01 at 1 h, p <
0.001 at 24 h) in soft tissue than in skeletal tissue (1.5 0.5%ID/g, 4.2 μg
of Pt/g at 1 hand 0.7  0.1%ID/g, 2 μg of Pt/g at 24 h). In contrast,
195mPt-cisplatin showed more uptake in soft tissue (4.8  1.0%ID/g, 5.4
μg of Pt/g) compared with skeletal tissue (2.3  0.5%ID/g, 2.6 μg of Pt/
g) at 1 hafter injection, and showed equal uptake in soft vs. skeletal tissue
(1.7  0.2%ID/g, 1.9 μg of Pt/g) at 24 h.
Finally, we compared the uptake of 195mPt in the skeletal tissue of
metastatic tibial lesions vs. uptake in the entire skeleton of the mice
(Fig. 4F). 195mPt-BP showed two-fold higher accumulation in skeletal
tissue (6.6  0.9%ID/g, 18.4 μg of Pt/g at 1 hand 4.3  0.8%ID/g, 12 μg
of Pt/g at 24 h) than 195mPt-cisplatin (3.4 1.2%ID/g, 3.8 μg of Pt/g at 1
hand 2.1  0.4%ID/g, 2.4 μg of Pt/g at 24 h). Strikingly, 195mPt-BP
accumulation (9.8  0.7%ID/g, 27.2 μg of Pt/g at 1 hand 7.8  0.5%ID/
g, 21.7 μg of Pt/g at 24 h) was much higher in the skeletal tissue of tibial
lesions than in the entire skeleton of the mice at 1 h and 24 h. In contrast,
195mPt-cisplatin showed equal levels of 195mPt accumulation (4.1  1.0%
ID/g, 4.6 μg of Pt/g at 1 hand 2.7 0.5%ID/g, 3 μg of Pt/g at 24 h) in the
lesions vs. the entire skeleton.
In summary, our data clearly confirm that 195mPt-BP specifically ac-
cumulates in the metastatic lesions for our prostate cancer cell–induced
intratibial bone metastasis model.
3.3. Targeted delivery of 195mPt promotes radiation-induced DNA damage
and apoptosis of metastatic tumor cells
To differentiate between bone marrow (dark purple) and tumor re-
gions (light purple or purplish-pink), whole tibia sections treated with
various types of Pt-based drugs were stained with H&E (14 days after
start of treatment) (Fig. 5A–H). This staining confirmed the presence of
tumor cell mass within the bone marrow and surrounding tibial lesions.
One specific lesion treated with 195mPt-BP showed the presence of a
necrotic tumor region (Fig. 5D).
Fig. 2. Validation of intratibial bone
metastases model using micro-SPECT/
CT and high-resolution micro-CT im-
aging. (A) Percentage of injected dose
(%ID/g) of 99mTc-MDP in the tibial
lesion and contralateral control tibia
after W5 as quantified from the micro-
SPECT/CT images. (data from 5 mice
per group are presented; paired t-test;
**p < 0.01; ***p < 0.001). (B) 99mTc-
MDP uptake (tibial lesion-to-control
tibia ratio) at W1, W3, and W5 (data
from 5 mice per group are presented;
unpaired t-test; **p < 0.01). Quantifi-
cation of the relative change in (C)
bone volume fraction (BV/TV) and (D)
bone volume (BV) of tibial lesions
normalized to contralateral control
tibia induced by breast or prostate
cancer cell intratibial injection. (two-
way ANOVA with a Bonferroni posthoc
test; **p  0.01; ***p  0.001). 3D
visualization of metastatic tibial lesions
at W5 induced by intratibial injection
of breast (E) and prostate (F) cancer
cells using CTVox (Bruker MicroCT,
Kontich, Belgium).
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Immunohistochemical staining of γ-H2AX, a biomarker specific for
double-strand DNA breaks, confirmed DNA damage caused by either
radiation or interstrand crosslinking of DNA by Pt-based drugs [16,34]
(Fig. 5I–L). Highest numbers of dark-stained γ-H2AX-positive tumor cells
were observed upon 195mPt-BP treatment (Fig. 5L). Moreover, apoptosis
within the tumor region was examined by visualization of DNA fragments
corresponding to apoptosis [35] (Fig. 5M–P). Similarly, the highest
numbers of dark-stained apoptotic tumor cells within the tumor region
were observed upon 195mPt-BP treatment (Fig. 5P). Subsequently, we
quantified the percentage of γ-H2AX positive and apoptotic areas within
the tumor regions. The γ-H2AX-positive tumor cell area within the tumor
region for mice treated with 195mPt-BP (1.66 0.4%) was 4.6-fold higher
than 195mPt-cisplatin (0.36  0.1%), 11-fold higher than radio-inactive
Pt-BP (0.15  0.1%), and 32-fold higher than saline control (0.05 
0.04%) (Fig. 5Q). Similarly, the apoptotic tumor cell area within the
tumor for mice treated with 195mPt-BP (0.92 0.5%) was 3.4-fold higher
than treatment of mice with 195mPt-cisplatin (0.27  0.1%), 3.5-fold
higher than radio-inactive Pt-BP (0.26  0.2%), and 5.4-fold higher
than saline control (0.17  0.02%) (Fig. 5R). In conclusion, 195mPt-BP
treatment caused DNA damage and apoptosis in tumor cells more effi-
ciently than all other treatment groups.
Finally, potential cytotoxic side-effects of 195mPt on kidneys were
evaluated histologically (Fig. S5). This analysis did not reveal morpho-
logical abnormalities following either 195mPt-cisplatin or 195mPt-BP
treatment. Moreover, radiation-induced DNA damage or apoptosis were
not observed in kidney tissue, as evidenced by the absence of positive
γ-H2AX and apoptosis immunohistochemical staining.
4. Discussion
Radionuclides that combine abundant emission of low-energy Auger
electrons with chemotherapeutic activity are highly attractive for cancer
therapy because of their dual action against cancer cells. Therefore,
previous in vitro and in vivo studies have explored the antitumor po-
tential of Auger electron-emitting 195mPt-radionuclides through the
incorporation of 195mPt in cisplatin [1]. However, undesired
dose-limiting side-effects of 195mPt-cisplatin (e.g. nephrotoxicity and
ototoxicity) were comparable to radio-inactive cisplatin and caused by
non-targeted tissue uptake [5]. Only few studies have evaluated the
toxicity of 195mPt associated with non-specific tissue or organ uptake [36,
37]. Consequently, dose-limiting effects of clinically used cisplatin still
hampers clinical translation of 195mPt as a therapeutic agent. To target
195mPt to bone metastases, the present study functionalized radioactive
195mPt with a bone-targeting bisphosphonate ligand (195mPt-BP). We
demonstrated that BP ligands targeted 195mPt effectively to metabolically
active bone in metastatic lesions, while single systemic administration of
195mPt-BP resulted in DNA damage and apoptosis of cancer cells.
This promising proof of concept could not have been obtained
without a suitable bone metastasis model. However, to the best of our
knowledge, standardized bone metastasis models are not yet available.
Therefore, we established an intratibial bone metastasis model in mice to
i) monitor 195mPt accumulation in a localized bone metastasis relative to
a contralateral control tibia in the same mouse; ii) ensure reproducibility
with limited morbidity; and iii) minimize remote metastatic burden for
the mice [38]. We induced this intratibial bone metastasis model using
Fig. 3. Biodistribution of 195mPt-BP and 195mPt-cisplatin in prostate cancer cell–induced intratibial lesions. Representative micro-SPECT/CT images showing bio-
distribution of 195mPt-BP (A) and 195mPt-cisplatin (B) in control tibia (left) and tibial lesion (right) at 1 h, 24 h, and 168 h after systemic administration. White ar-
rowheads correspond to the tibial lesions.
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either human breast or prostate cancer cells and validated metastatic
lesion formation based on bone metabolic activity (99mTc-MDP;
micro-SPECT/CT imaging) and alterations in bonemorphology (mixed or
osteolytic changes in tibial bone; ex-vivo high-resolution micro-CT im-
aging). Upon intratibial breast cancer cell injection, we observed osteo-
lytic lesions, reduced bone metabolism, and formation of additional
metastases, predominantly in the spine. In contrast, intratibial injection
of prostate cancer cells resulted in the formation of a localized bone
metastasis characterized by high bone metabolic activity and mixed
osteosclerotic/osteolytic tibial lesions of high metabolic activity. There-
fore, we selected the prostate cancer cell–induced intratibial metastasis
model to evaluate the bone tumor-targeting and therapeutic efficacy of
195mPt-BP vs. 195mPt-cisplatin as control. Before evaluation of the bone
tumor-targeting potential of 195mPt-BP, successful establishment of
intratibial bone metastasis was confirmed using 18F-NaF PET imaging to
avoid competitive inhibition between MDP and 195mPt-BP. 18F-NaF binds
Fig. 4. Quantification of 195mPt-BP and 195mPt-cisplatin biodistribution in prostate cancer-induced intratibial bone metastasis model. (A) Percentage of injected dose
(%ID/g) of 195mPt-BP (n ¼ 3) and 195mPt-cisplatin (n ¼ 4) in tibial lesions after 7 days as quantified from the micro-SPECT/CT images. (B) Percentage of injected dose
(%ID/g) of 195mPt-BP and 195mPt-cisplatin in tibial lesion normalized to 195mPt uptake in contralateral control tibia within individual mice. (C) Percentage of injected
dose (%ID/g) of 195mPt-BP and 195mPt-cisplatin in soft tumor tissue surrounding tibial lesions based on CT thresholding within the tibial lesion (VOI). (D) Percentage of
injected dose (%ID/g) of 195mPt-BP and 195mPt-cisplatin in soft tumor tissue surrounding tibial lesions normalized to 195mPt uptake in contralateral control tibia within
individual mice. (E) Percentage of injected dose (%ID/g) of 195mPt-BP and 195mPt-cisplatin in soft and skeletal tissues of entire mice at 1 h and 24 h. (F) Percentage of
injected dose (%ID/g) of 195mPt-BP and 195mPt-cisplatin in mice as quantified in skeletal tissue of tibial lesion and skeletal tissue of entire mice where the region of
interest (ROI) with the location of the edge of the ROI contour represents 75% of maximum intensity. Solid lines and dotted lines correspond to 195mPt uptake in
skeletal tissue of the entire mouse and skeletal tissue of tibial lesion, respectively. (Data from three to four mice per group; *p  0.05; **p  0.01; ***p  0.001; ****p
 0.0001; two-way ANOVA with a Bonferroni posthoc test).
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to bone by replacing hydroxyl groups, whereas bisphosphonates bind to
calcium. Consequently, 18F-NaF PET imaging was selected as imaging
modality to confirm the formation of intratibial bone metastases [39].
Similar to our previous data on biodistribution of 195mPt-BP [15], we
herein observed specific accumulation of 195mPt-BP in bone. Excitingly,
accumulation in metastatic bone lesions was even higher already at 1
hafter administration compared with 195mPt-cisplatin. This high accu-
mulation in metastatic lesions can be attributed to the enhanced bone
metabolic activity in bone lesions, as 195mPt-BP accumulation was
negligible in tibia with inferior lesion formation (<2% change in bone
volume). In contrast, 195mPt-cisplatin accumulated specifically in soft
off-target tissues. However, none of the tumor-bearing mice showed
weight loss, which contrasts recent findings by Aalbersberg et al. who
used a 4.7 0.2 MBqdose of 195mPt-cisplatin in different strains of female
mice [40]. Specific targeting of 195mPt-BP in metastatic lesions resulted in
the accumulation of ~22 μg of Pt/g, while almost 75% of 195mPt was
retained in the metastatic lesions until day 7. Likewise, selective accu-
mulation of 195mPt-BP also increased the 195mPt dose in soft tumor tissue
surrounding tibial lesions. Thus, 195mPt-BP uptake is accelerated by high
bone metabolic activity in tibial lesions. Clinically, these findings are
relevant since lesions of bone metastases in cancer patients are also
characterized by high metabolic activity [41]. Moreover, 195mPt-BP
facilitated noninvasive detection of the tibial lesion within 1 hafter sys-
temic administration, which opens up new avenues of research on
theranostic application of 195mPt-BP complexes.
To evaluate potential radiotherapeutic effects of 195mPt-BP, we
compared its therapeutic efficacy with non-radioactive Pt-BP and saline
controls to study additional effects of Auger electrons emitted by 195mPt.
Previous work explored the therapeutic potential of Auger electrons
emitted from, for example, 123I, 125I, and 111In, which were conjugated to
Fig. 5. Representative histochemical and immunohistochemical images of tibial lesions in a prostate cancer cell–induced bone metastasis model 14 days after
treatment. (A–D) Representative overview of H&E-stained tibial lesions. The rectangular box within each group (A–D) is magnified (10) in (E–H). (BM: bone marrow
stained as dark purple; T: tumor stained as light purple/purplish-pink; NR: necrotic region; B: bone stained as light pink). (I–L) Immunostaining of γ-H2AX–positive
tumor cells (dark brown) in the tibial lesions correspond to double-strand DNA breaks in tumor cells. (M–P) Detection of apoptotic tumor cells (dark brown) in the
tibial lesions based on DNA fragmentation. (Q) Percentage of γ-H2AX–positive tumor cell area relative to the total tumor area. (R) Percentage of apoptotic tumor cell
area relative to the total tumor area. Scale bars correspond to 2 mm (A–C), 5 mm (D), and 200 μm (E–P). H&E: hematoxylin and eosin. Data from three to four mice per
group, six to nine histological sections analyzed for each mouse. (*p  0.05; **p  0.01; ***p  0.001; ****p  0.0001; one-way ANOVA with a Tukey posthoc test.)
(For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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a monoclonal antibody or nucleus-specific peptide for targeting purposes
[42–44]. As 195mPt emits Auger electrons more efficiently, we function-
alized 195mPt with BP ligands to target these Auger emitters as close as
possible to metastatic tibial lesions of high metabolic activity. Specific
accumulation of 195mPt enhanced DNA damage, as previously predicted
by Monte Carlo simulations, which showed that 195mPt radionuclides in
close proximity to DNA induce cell death as caused by high-LET (linear
energy transfer) α particles (5.3 MeV) [6,45]. Bone tumor–targeted de-
livery of 195mPt-BP to metastatic tibial lesions damaged DNA in cancer
cells 4.5-fold more efficiently than 195mPt-cisplatin and even 11-fold
more efficiently than non-radioactive Pt-BP. These results were
affirmed by a significant increase in apoptotic tumor cells upon 195mPt-BP
treatment. Furthermore, one (out of 3) metastatic lesions in mice treated
with 195mPt-BP showed a necrotic region (~30%). Interestingly, this
specific metastatic lesion also exhibited the most pronounced accumu-
lation of 195mPt-BP. Similar necrosis was also observed previously after
223Ra (Xofigo) treatment in a patient-derived LuCaP 58 prostate cancer
xenograft model [46]. These observations confirm that the therapeutic
effect of low-LET Auger electrons at high concentrations is based on
similar principles as conventional high-LET α-radiotherapy for treatment
of bone metastases [1].
The present study highlights several advantages of 195mPt-BP com-
plexes for medical treatment of bonemetastases based on their diagnostic
and therapeutic potential. First, rapid uptake of 195mPt-BP bone meta-
static lesions confirms that 195mPt-BP targeting is specific for bone tumors
of high metabolic activity. These novel findings support the design of
new theranostic agents which ‘detect and treat’ patients with bone me-
tastases of high metabolic activity using Auger electron-emitting 195mPt
radionuclides. Second, 195mPt-BP accumulation in bone metastatic le-
sions also increases 195mPt distribution within soft tumor tissue sur-
rounding metastatic lesions, which suggests that the increased DNA
damage in the tumor region is caused by 195mPt release into the meta-
static lesion due to acidifying osteolytic effects. Third, targeting of
195mPt-BP in metastatic lesions allows for higher dosing of 195mPt
compared with 195mPt-cisplatin. Importantly, the targeted accumulation
of 195mPt-BP to metabolically active metastatic lesions also enhanced
DNA damage to tumor cells 4.5-fold without causing nephrotoxicity.
Finally, therapeutic anticancer effects of Pt-BP (expressed as DNA dam-
age in tumor cells) increases 11-fold when using Auger-emitting 195mPt
instead of radio-inactive Pt. This radiotherapeutic efficacy of 195mPt-BP
was never shown before, which stresses the novelty and potential impact
of our approach. Consequently, effective bone tumor-targeting of 195mPt-
BP paves the way for future clinical applications of 195mPt-BP complexes
as a theranostic agent to maximize therapeutic efficacy and minimize
systemic toxicity.
Nevertheless, several limitations of the present study should be
highlighted. For instance, a higher radioactive 195mPt dose was used for
195mPt-BP compared to 195mPt-cisplatin for practical reasons explained in
the experimental section. Proper follow-up studies are required to
compare therapeutic effects at equal doses of both types of 195mPt-drugs.
Moreover, it should be emphasized that mice only received a single dose
of Pt-based drugs at relatively low Pt concentrations. This experimental
procedure might have compromised the chemotherapeutic efficacy of the
Pt-based drugs as compared to multiple dosing regimens of clinically
applied chemotherapy. Furthermore, the release of 195mPt from 195mPt-
BP complexes was only confirmed indirectly by histological observations
on tumor cell DNA damage and apoptosis. Although we previously
showed in vivo release of 195mPt from 195mPt-BP by elemental mapping
using laser ablation inductively coupled plasma mass spectrometry [15],
immunohistochemical techniques to quantify tumor cell DNA damage
and apoptosis were not compatible with this elemental mapping tech-
nique, which requires poly(methyl methacrylate) tissue embedding [47].
In addition, the localization of 195mPt in bone marrow warrants further
investigations to fully understand the effects of 195mPt-BP on healthy
bone cells. Finally, 195mPt toxicity will still be a major concern for clinical
translation, and hence needs further investigation using detailed dosing
studies.
Therefore, further preclinical studies in larger animals and upscaling
facilities are required before clinical translation becomes feasible. Spe-
cifically, these R&D efforts should focus on i) unraveling the relationship
between therapeutic efficacy and specific radio- and chemotherapeutic
activity of 195mPt; ii) determining the minimum dosage required to
effectively kill metastatic tumor cells while minimizing toxicity to sur-
rounding healthy bone cells; and iii) upscaling the production of 195mPt-
BP complexes under good manufacturing practice conditions.
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